Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Msci Inc (MSCI) Price & Performance

Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Msci Inc — how do they compare? Quest Diagnostics Inc trades at $238.51 (market cap $26.21B), while Msci Inc trades at $564.62 (market cap $40.84B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays the higher dividend (1.46%). Which is the better fit depends on your goals.

DGXMSCI
Market Cap
$26.21B$40.84B
Sector
HealthFinancials
52-Week High
$238.50$643.83
52-Week Low
$173.49$511.84
Enterprise Value
$31.97B$47.00B
Dividend Yield
1.45%1.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Msci Inc

MSCI trades at $559.73, down 0.59% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported Q2 2026 earnings of $4.94 per share, slightly missing expectations, but maintains strong fundamentals with a 40.73% net income margin and $3.13 billion in 2025 revenue. Recent developments include the completed acquisition of First Street and a strategic partnership with UBS to enhance private markets transparency.

The stock presents a compelling opportunity with a consensus price target of $728.14, implying significant upside, supported by robust profitability and recurring revenue streams. Key risks include high valuation multiples, such as a P/E of 30.71, and substantial long-term debt of $4.51 billion, which could pressure equity if interest rates rise.

Returns comparison

Trailing returns across standard periods

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI